FindTrial
Sign In

Probiotic (Lactobacillus zeae TISTR 2529 and Lactobacillus reuteri TISTR 2736, 1:1 ratio)),placebo

2 trials

Sponsors

Thailand Institute of Scientific and Technological Research (TISTR), phramongkutklao hospital

Conditions

Non alcoholic fatty liver disease, fatty liver NAFLDParticipants must present at least two of the following metabolic risk factors: elevated triglycerides (more than 150 mg/dL), low HDL cholesterol (less than 40 mg/dL for men or less than 50 mg/dL for women), high blood pressure (more than 130/85 mmHg or on antihypertensive medication), or elevated fasting glucose (more than 100 mg/dL or on antidiabetic treatment). Additionally, all participants must have a confirmed diagnosis of fatty liver, determined by FibroScan, ultrasound, MRI, or liver bio

Phase 2

Testing Probiotic Supplements for Improving Metabolism and Liver Health in People with Obesity
Active, not recruitingTCTR20250805002
Thailand Institute of Scientific and Technological Research (TISTR)Participants must present at least two of the following metabolic risk factors: elevated triglycerides (more than 150 mg/dL), low HDL cholesterol (less than 40 mg/dL for men or less than 50 mg/dL for women), high blood pressure (more than 130/85 mmHg or on antihypertensive medication), or elevated fasting glucose (more than 100 mg/dL or on antidiabetic treatment). Additionally, all participants must have a confirmed diagnosis of fatty liver, determined by FibroScan, ultrasound, MRI, or liver bio
Start: 2023-08-30Target: 40Updated: 2026-08-03
PROBIOTIC SUPPLEMENT VERSUS PLACEBO FOR DECREASE STEATOSIS IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)
Active, not recruitingTCTR20250818026
phramongkutklao hospitalNon alcoholic fatty liver disease, fatty liver NAFLD
Start: 2023-04-20Target: 50Updated: 2026-08-03